Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06133062

Atezolizumab and Bevacizumab with Proton Radiotherapy for Unresectable Hepatocellular Carcinoma (ProtonAB)

Investigation of Antitumor Immune Response in Patients with Unresectable Hepatocellular Carcinoma Undergoing Proton Radiotherapy Combined with Atezolizumab and Bevacizumab

Sponsor: Chang Gung Memorial Hospital

Conditions Hepatocellular Carcinoma Non-resectable

Interventions Atezolizumab Bevacizumab Proton radiotherapy

Updated 6 times since 2023 Last updated: Feb 16, 2025 Started: Nov 16, 2023 Primary completion: Sep 30, 2028 Completion: Sep 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatocellular Carcinoma Non-resectable and is currently actively recruiting participants. Chang Gung Memorial Hospital leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Mar 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Dec 2023 — Mar 2024 [monthly]

Recruiting PHASE2

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang Gung Memorial Hospital

Data source: Chang Gung Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taoyuan, Taiwan